ALTERITY THERAPEUTICS LTD
A clinical-stage biotech developing novel treatments for neurodegenerative diseases.
ATHE | US
Overview
Corporate Details
- ISIN(s):
- US7397272045 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- LEVEL 3, 460 BOURKE STREET, 0 MELBOURNE
- Sector:
- Manufacturing
Description
Alterity Therapeutics is a clinical-stage biotechnology company focused on developing novel treatments for neurodegenerative diseases. The company's lead drug candidate, ATH434, is a first-in-class small molecule designed to address the underlying pathology of these conditions by inhibiting the aggregation of pathological proteins. ATH434 is being evaluated in clinical trials for the treatment of Parkinsonian disorders, including Multiple System Atrophy (MSA). The company's therapeutic approach aims to modify the course of disease rather than merely treating symptoms. In addition to its lead program, Alterity Therapeutics maintains a drug discovery platform to generate new therapeutic candidates for a range of neurodegenerative diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ALTERITY THERAPEUTICS LTD filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ALTERITY THERAPEUTICS LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ALTERITY THERAPEUTICS LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
